Covidien (COV) Tops Q4 EPS by 10c; Gives Slight Boost to FY12 Revs Outlook

Covidien (NYSE: COV) reported Q4 EPS of $1.13, $0.10 better than the analyst estimate of $1.03. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.92 billion.

On an operational basis, excluding the impact of foreign exchange, Covidien now estimates that total Company sales in FY12 will increase 3% to 5% in fiscal 2012, about one percentage point above its prior guidance.

For earnings history and earnings-related data on Covidien (COV) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance